Prenuvo: The company raised $70 million of Series A venture funding in a deal led by Felicis Ventures on October 18, 2022. Steel Perlot, Rande Gerber, Cindy Crawford, Tony Fadell, Timothy A. Springer, and Anne Wojcicki also participated in the round. The company is a developer of a whole-body magnetic resonance imaging scan technology designed to detect cancer and other chronic illness.
Inversago Pharma: The company raised CAD 95 million of Series C venture funding in a deal led by New Enterprise Associates on October 17, 2022. adMare BioInnovations, Amgen Ventures, Fonds de solidarité FTQ, AmorChem, Genesys Capital, T1D Fund and Forbion also participated in the round. The company is a developer of medical drugs intended to treat and cure metabolic disorders.
Orionis Biosciences: The company raised $55 million of venture funding from Novartis, Cormorant Asset Management and other undisclosed investors on October 19, 2022. The company is a developer of therapeutic agents designed to advance novel small-molecule cancer medicines.
Univercells: The company raised EUR 44 million of Series D venture funding from Société Régionale d’Investissement de Wallonie, AdBio partners, and 3d investors on October 19, 2022. Global Health Investment Fund, Adjuvant Capital, Amerigo Capital, TheClubDeal, and Federal Holding and Investment Company also participated in the round. The company is a developer of vaccines and bio-therapeutics intended to address global health challenges.
Nucleome Therapeutics: The company raised GBP 37.5 million of Series A venture funding in a deal led by M Ventures on October 19, 2022. Johnson & Johnson Innovation – JJDC, Pfizer Ventures, British Patient Capital, and Oxford Science Enterprises also participated in the round. The company is a developer of a therapeutics technology platform designed to connect disease-linked variants in the dark matter of the genome.
OSSIO: The company raised $38.5 million of Series C venture funding in a deal led by MVM Partners on October 17, 2022. Other undisclosed investors also participated in the round. The company is an operator of an orthopedic fixation business intended to provide a replacement for metal implants.
Anokion: The company raised $35 million of venture funding in a deal led by Pfizer on October 18, 2022. The company is a developer of antigen-specific immunotherapy designed to offer services for antigen-specific immune tolerance.
PIC Therapeutics: The company raised $35 million of Series A venture funding in a deal led by OrbiMed on October 19, 2022. Advent Life Sciences, Lumira Ventures, Belinda Termeer, and Harrington Discovery Institute/University Health Holdings also participated in the round. The company is an operator of a biotechnology business intended to focus on changing cancer treatment by developing a new generation of therapeutics.
Surge Therapeutics: The company raised $26 million of Series A venture funding in a deal led by DHVC on October 17, 2022. Intuitive Ventures, Khosla Ventures, Pitango Venture Capital, 8VC, Alumni Ventures and other undisclosed investors also participated in the round.The company is a provider of healthcare services intended to provide immunotherapy to cancer patients.
Xentria: The company raised $25 million of venture funding from undisclosed investors on October 18, 2022.The company is a developer of drugs intended to help solve medical unmet needs through meaningful patient engagement and novel scientific strategy.
Empyrean Neuroscience: The company raised $22 million of Series A venture funding from undisclosed investors on October 18, 2022.The company is a developer of a genetic engineering platform intended to transform how severe neuropsychiatric and neurologic diseases are treated.
Myrtelle: The company raised $15.7 million of venture funding from undisclosed investors on October 17, 2022, putting the company’s pre-money valuation at $100 million.The company is an operator of a gene therapy business intended to offer innovative clinical trials for the treatment of the rare monogenetic disorder.
HMNC Brain Health: The company raised EUR 14.3 million of venture funding led by Carsten Maschmeyer Family Office, Jahr Holding and Guntard Gutmann Family Office on October 20, 2022. Josef Ackermann, Toni Kroos, Wilhelm Beier and Hans Kompernaß, also participated in the round. The company is a developer of precision therapies intended for depression and other neuropsychiatric disorders.
Axis Spine Technologies: The company raised GBP 10.8 million of venture funding in a deal led by Mercia Asset Management on October 18, 2022. MedTex Ventures and other undisclosed investors also participated in the round. The company is a developer of spinal implants designed to offer greater intra-operative correction capabilities without the risks associated with small moving parts that can wear out.
Actuate Therapeutics: The company raised $11.2 million of venture funding from undisclosed investors on October 18, 2022.The company is an operator of a biopharmaceutical business focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis.
Enhanc3D Genomics: The company raised GBP 10.0 million of Series A venture funding in a deal led by BGF and Parkwalk Advisors on October 20, 2022, putting the company’s pre-money valuation at GBP 9.13 million. Bioqube Ventures also participated in the round. The company is a developer of a biotechnology solution designed to develop tools for large-scale analysis of genetic variations and gene function.
Access Vascular: The company closed on $10 million of venture funding through a combination of debt and equity on October 19, 2022.The company is a developer of vascular access devices designed to address the most common and costly complications in intravenous therapy.
Acclinate: The company raised $4.9 million of venture funding from undisclosed investors on October 19, 2022.The company is a developer of a digital health analytics platform designed to assist biopharmaceutical research organizations in increasing the representation and diversity of their genomic research and clinical trials.
